JP2020510661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510661A5 JP2020510661A5 JP2019547093A JP2019547093A JP2020510661A5 JP 2020510661 A5 JP2020510661 A5 JP 2020510661A5 JP 2019547093 A JP2019547093 A JP 2019547093A JP 2019547093 A JP2019547093 A JP 2019547093A JP 2020510661 A5 JP2020510661 A5 JP 2020510661A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- xrpd
- anhydrous
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000013078 crystal Substances 0.000 claims 11
- 150000004682 monohydrates Chemical class 0.000 claims 6
- 229960002100 cefepime Drugs 0.000 claims 4
- HVFLCNVBZFFHBT-ZKDACBOMSA-O cefepime(1+) Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-O 0.000 claims 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- -1 (Trans-4- (2-aminoethylamino) cyclohexyl) acetamide Chemical compound 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- PFZUWUXKQPRWAL-NOLJZWGESA-N NCCN[C@H]1CC[C@H](CC(N[C@H]2Cc3cccc(C(O)=O)c3OB2O)=O)CC1 Chemical compound NCCN[C@H]1CC[C@H](CC(N[C@H]2Cc3cccc(C(O)=O)c3OB2O)=O)CC1 PFZUWUXKQPRWAL-NOLJZWGESA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023007546A JP2023061946A (ja) | 2017-03-06 | 2023-01-20 | β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762467750P | 2017-03-06 | 2017-03-06 | |
| US201762467752P | 2017-03-06 | 2017-03-06 | |
| US62/467,752 | 2017-03-06 | ||
| US62/467,750 | 2017-03-06 | ||
| US201762564989P | 2017-09-28 | 2017-09-28 | |
| US201762564990P | 2017-09-28 | 2017-09-28 | |
| US62/564,989 | 2017-09-28 | ||
| US62/564,990 | 2017-09-28 | ||
| PCT/US2018/020968 WO2018165048A1 (en) | 2017-03-06 | 2018-03-05 | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023007546A Division JP2023061946A (ja) | 2017-03-06 | 2023-01-20 | β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510661A JP2020510661A (ja) | 2020-04-09 |
| JP2020510661A5 true JP2020510661A5 (enExample) | 2021-04-08 |
| JP7634934B2 JP7634934B2 (ja) | 2025-02-25 |
Family
ID=63448038
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547093A Active JP7634934B2 (ja) | 2017-03-06 | 2018-03-05 | β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用 |
| JP2023007546A Pending JP2023061946A (ja) | 2017-03-06 | 2023-01-20 | β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023007546A Pending JP2023061946A (ja) | 2017-03-06 | 2023-01-20 | β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US11091505B2 (enExample) |
| EP (1) | EP3592362B1 (enExample) |
| JP (2) | JP7634934B2 (enExample) |
| KR (1) | KR102603489B1 (enExample) |
| CN (2) | CN117398398A (enExample) |
| AU (1) | AU2018230991B2 (enExample) |
| BR (1) | BR112019018447A2 (enExample) |
| CA (1) | CA3055253A1 (enExample) |
| ES (1) | ES3015371T3 (enExample) |
| HR (1) | HRP20250459T1 (enExample) |
| IL (2) | IL268981B2 (enExample) |
| MA (1) | MA47743A (enExample) |
| MY (1) | MY196966A (enExample) |
| PH (1) | PH12019502037B1 (enExample) |
| PL (1) | PL3592362T3 (enExample) |
| SG (1) | SG11201908181XA (enExample) |
| WO (1) | WO2018165048A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2893943C (en) | 2012-12-07 | 2021-03-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| JP6346904B2 (ja) | 2013-01-10 | 2018-06-20 | ベナトルクス ファーマシューティカルズ，インク． | ベータ−ラクタマーゼ阻害剤 |
| WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP3882252B1 (en) | 2014-06-11 | 2025-11-19 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2017044828A1 (en) | 2015-09-11 | 2017-03-16 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP3494121B1 (en) | 2016-08-04 | 2021-10-06 | Venatorx Pharmaceuticals, Inc. | Boron-containing compounds |
| PH12019502037B1 (en) | 2017-03-06 | 2024-06-05 | Everest Medicines Singapore Pte Ltd | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| EP3630783A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | PENICILLIN-BINDING PROTEIN INHIBITORS |
| US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2019226931A1 (en) | 2018-05-25 | 2019-11-28 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US20220054513A1 (en) * | 2018-09-12 | 2022-02-24 | VenatoRx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021454A (en) | 1911-01-23 | 1912-03-26 | Thomas Ernest Davis | Serving-table. |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| IN2012DN03023A (enExample) | 2004-01-26 | 2015-07-31 | Merck Sharp & Dohme | |
| NZ550522A (en) | 2004-03-30 | 2010-08-27 | Millennium Pharm Inc | Synthesis of boronic ester and acid compounds |
| CN1965838A (zh) * | 2005-11-17 | 2007-05-23 | 李海超 | 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物 |
| CN101129382B (zh) | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| BRPI0820532A2 (pt) | 2007-11-13 | 2012-07-10 | Protez Pharmaceuticals Inc | inibidores de beta-lactamase |
| US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| JP5038509B2 (ja) | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
| RU2599791C2 (ru) | 2010-08-10 | 2016-10-20 | Ремпекс Фармасьютикэлз, Инч. | Циклические бороновые кислотно-эфирные производные и их использование в терапии |
| AU2011373912B2 (en) * | 2011-07-26 | 2016-09-29 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
| KR101288157B1 (ko) | 2011-12-07 | 2013-07-19 | 백병하 | 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제 |
| JP5798495B2 (ja) | 2012-01-13 | 2015-10-21 | 住友理工株式会社 | 配線体接続構造体 |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| DE102012101680A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| CA2893943C (en) | 2012-12-07 | 2021-03-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| JP6324409B2 (ja) | 2013-01-04 | 2018-05-16 | レンペックス・ファーマシューティカルズ・インコーポレイテッド | ボロン酸誘導体及びその治療的使用 |
| AU2014204045B2 (en) | 2013-01-04 | 2018-10-18 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| JP6346904B2 (ja) | 2013-01-10 | 2018-06-20 | ベナトルクス ファーマシューティカルズ，インク． | ベータ−ラクタマーゼ阻害剤 |
| WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2015051101A1 (en) * | 2013-10-02 | 2015-04-09 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| WO2015157618A1 (en) | 2014-04-11 | 2015-10-15 | The Texas A&M University System | Novel inhibitors of the new delhi metallo beta lactamase (ndm-1) |
| EP3882252B1 (en) | 2014-06-11 | 2025-11-19 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US20150361107A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Orally bioavailable beta-lactamase inhibitors |
| EP3189841B1 (en) | 2014-09-04 | 2023-11-22 | Shionogi & Co., Ltd. | Pharmaceutical preparation comprising cephalosporin having catechol groups |
| US10364257B2 (en) | 2014-12-19 | 2019-07-30 | Rempex Pharmaceuticals, Inc. | Apparatus and continuous flow process for production of boronic acid derivatives |
| WO2017044828A1 (en) | 2015-09-11 | 2017-03-16 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN105801610B (zh) | 2016-04-19 | 2018-05-18 | 武汉维舜医药科技有限公司 | 新型广谱β-内酰胺酶抑制剂 |
| JP7060245B2 (ja) | 2016-06-30 | 2022-04-26 | キューペックス バイオファーマ， インコーポレイテッド | ボロン酸誘導体およびその治療的使用 |
| EP3494121B1 (en) | 2016-08-04 | 2021-10-06 | Venatorx Pharmaceuticals, Inc. | Boron-containing compounds |
| PH12019502037B1 (en) | 2017-03-06 | 2024-06-05 | Everest Medicines Singapore Pte Ltd | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| WO2019226931A1 (en) | 2018-05-25 | 2019-11-28 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US20220054513A1 (en) | 2018-09-12 | 2022-02-24 | VenatoRx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor |
| AU2019386849B2 (en) | 2018-11-29 | 2025-07-24 | VenatoRx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor and uses thereof |
-
2018
- 2018-03-05 PH PH1/2019/502037A patent/PH12019502037B1/en unknown
- 2018-03-05 MY MYPI2019005139A patent/MY196966A/en unknown
- 2018-03-05 WO PCT/US2018/020968 patent/WO2018165048A1/en not_active Ceased
- 2018-03-05 JP JP2019547093A patent/JP7634934B2/ja active Active
- 2018-03-05 HR HRP20250459TT patent/HRP20250459T1/hr unknown
- 2018-03-05 EP EP18763383.9A patent/EP3592362B1/en active Active
- 2018-03-05 CN CN202311312855.3A patent/CN117398398A/zh active Pending
- 2018-03-05 SG SG11201908181X patent/SG11201908181XA/en unknown
- 2018-03-05 PL PL18763383.9T patent/PL3592362T3/pl unknown
- 2018-03-05 CA CA3055253A patent/CA3055253A1/en active Pending
- 2018-03-05 BR BR112019018447-3A patent/BR112019018447A2/pt active IP Right Grant
- 2018-03-05 IL IL268981A patent/IL268981B2/en unknown
- 2018-03-05 US US16/491,116 patent/US11091505B2/en active Active
- 2018-03-05 ES ES18763383T patent/ES3015371T3/es active Active
- 2018-03-05 MA MA047743A patent/MA47743A/fr unknown
- 2018-03-05 CN CN201880030083.5A patent/CN110678186A/zh active Pending
- 2018-03-05 KR KR1020197029086A patent/KR102603489B1/ko active Active
- 2018-03-05 AU AU2018230991A patent/AU2018230991B2/en active Active
-
2021
- 2021-06-21 US US17/353,377 patent/US11820784B2/en active Active
-
2023
- 2023-01-20 JP JP2023007546A patent/JP2023061946A/ja active Pending
- 2023-03-22 IL IL301591A patent/IL301591B1/en unknown
- 2023-09-27 US US18/476,050 patent/US12187752B2/en active Active
-
2024
- 2024-11-25 US US18/959,220 patent/US20250320235A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510661A5 (enExample) | ||
| JP2018115191A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| JP2017160233A5 (enExample) | ||
| JP2010514829A5 (enExample) | ||
| JP2018035160A5 (enExample) | ||
| JP2017531038A5 (enExample) | ||
| CA2727378A1 (en) | New co-crystal compound of rivaroxaban and malonic acid | |
| JP2020507589A5 (enExample) | ||
| JP2016522835A5 (enExample) | ||
| JP2014525470A5 (enExample) | ||
| JP2010514832A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JP2012508215A5 (enExample) | ||
| JP2010521516A5 (enExample) | ||
| CN109311852A (zh) | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 | |
| JP2012507535A5 (enExample) | ||
| RU2018114480A (ru) | Соли и твердые формы монобактамного антибиотика | |
| CN115315423A (zh) | 取代芳基类化合物 | |
| JP2008513510A5 (enExample) | ||
| JP2018530608A5 (enExample) | ||
| JP2016510768A5 (enExample) | ||
| JP2017507980A5 (enExample) | ||
| JP2014517848A5 (enExample) | ||
| JP2009040767A5 (enExample) |